{"analyses":[{"ciLowerLimit":"0.37","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.74","estimateComment":"Hazard ratio was estimated by Cox regression model.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis; Stratification factors: 17p deletion, risk status, geographic region.","nonInferiorityType":"SUPERIORITY","pValue":"0.0002","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.76","estimateComment":"Hazard ratio was estimated by Cox regression model.","groupDescription":"Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0003","paramType":"Hazard Ratio (HR)","paramValue":"0.54","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not estimable due to low number of participants with event.","groupId":"OG000","lowerLimit":"70.1","upperLimit":"NA","value":"87.8"},{"comment":"Median, lower limit and upper limit were not estimable due to low number of participants with event.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"194"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. The median OS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bendamustine at a dose of 70 milligrams per meter square (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Bendamustine + Rituximab Main Study"},{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG001","title":"Venetoclax + Rituximab Main Study"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants, with participants grouped according to randomized treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 8 years 5 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}